Radiopharm Theranostics, Ltd
Radiopharm Theranostics is dedicated to developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, addressing high unmet medical needs. The company is engaged in clinical trials, strategic partnerships, and advancing cancer research with a focus on precision oncology.
Industries
Nr. of Employees
small (1-50)
Radiopharm Theranostics, Ltd
Carlton South Vic 3053, Australia
Products
B7H3-targeted therapeutic — Phase I clinical program
An early-phase clinical program evaluating a B7H3-directed radiotherapeutic in patients with non-small cell lung cancer to assess safety and enable dose selection.
B7H3-targeted therapeutic — Phase I clinical program
An early-phase clinical program evaluating a B7H3-directed radiotherapeutic in patients with non-small cell lung cancer to assess safety and enable dose selection.
Services
Conduct of early-phase oncology clinical studies including trial initiation, site activation and study operations for radiopharmaceutical candidates.
Preclinical and translational development services for diagnostic and therapeutic radioconjugates through candidate selection and clinical transition.
Negotiation and establishment of supply agreements for clinical-grade radioisotopes to support manufacturing and clinical supply of radiopharmaceuticals.
Conduct of early-phase oncology clinical studies including trial initiation, site activation and study operations for radiopharmaceutical candidates.
Preclinical and translational development services for diagnostic and therapeutic radioconjugates through candidate selection and clinical transition.
Negotiation and establishment of supply agreements for clinical-grade radioisotopes to support manufacturing and clinical supply of radiopharmaceuticals.
Expertise Areas
- Radiopharmaceutical development
- Targeted radionuclide therapy
- Early-phase (Phase I) oncology clinical trials
- Radioisotope procurement and supply-chain management
Key Technologies
- Radioconjugates (therapeutic and diagnostic)
- Lutetium-177 radiotherapy
- Targeted radionuclide therapy (B7H3-directed)
- Clinical-grade radioisotope supply